You are here

Incysus Therapeutics to Present at the 2018 Bio Investor Forum

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced today that the Company will present at the 2018 BIO Investor Forum being held in San Francisco, CA on October 17-18.  William Ho, President and Chief Executive Officer of Incysus, will present a company overview.

  Who:   William Ho, President and Chief Executive Officer
       
  What:   Incysus Presentation at the BIO Investor Forum
       
  When:   Thursday, October 18, 2018 at 10:15 am PDT
       
  Where:   Westin St. Francis Hotel, Room Elizabethan A, 335 Powell Street, San Francisco, CA 94102

About BIO Investor Forum

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and BIO One-on-One Partnering™ meetings.  The forum will take place in San Francisco, CA at the Westin St. Francis on October 17th and 18th, 2018.

About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since the Company’s inception in early 2016, Incysus has filed two Investigational New Drug applications (IND) and has initiated several cancer programs in early pre-clinical stages.  The Company’s first program is targeted to leukemia and lymphoma patients and the IND related to this program was accepted by the FDA in late 2017.  The Company’s second program is targeted to treat patients with newly-diagnosed glioblastoma (GBM).  In collaboration with the University of Alabama at Birmingham (UAB), Incysus has advanced its technology and expects to begin both Phase 1 trials early next year.  For more information, visit www.incysus.com.

Contact:
Incysus Therapeutics, Inc.
(646) 820-8474
info@incysus.com

Tuesday, October 16, 2018 - 08:00